DAREON-Lung-1: DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy (clinicaltrials.gov) - Sep 30, 2026 - P3 | N=670 | Recruiting | Sponsor: Boehringer Ingelheim | Initiation date: Apr 2026 ➔ Nov 2025
Trial initiation date • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor • DLL3
|